Alpha 2.0
Login Register
» Authors » Jorge Lujan-Zilbermann

Jorge Lujan-Zilbermann

Explore the profile of Jorge Lujan-Zilbermann including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 492
Followers 0
Related Specialties
Pediatrics
Pathology
Infectious Diseases
Top 10 Co-Authors
Meredith G Warshaw
Brandy Rutledge
Patricia J Emmanuel
Peter L Havens
Charles B Stephensen
Kathleen Mulligan
Craig M Wilson
Rohan Hazra
Patrick Jean-Philippe
George K Siberry
Published In
Pediatr Infect Dis J
Fetal Pediatr Pathol
J Pediatr
Pediatrics
Vaccine
Affiliations
Soon will be listed here.
Recent Articles
1.
Revisiting FDA's 1995 Guidance on Bioequivalence Establishment of Topical Dermatologic Corticosteroids: New Research Based Recommendations
Ozdin D, Sharma N, Lujan-Zilbermann J, Colucci P, Kanfer I, Ducharme M
J Pharm Pharm Sci . 2018 Nov; 21(1):413-428. PMID: 30407906
Purpose: As per the US FDA guidance issued on June 2, 1995, the establishment of bioequivalence for topical dermatologic corticosteroids is based on comparing the pharmacodynamic (PD) effects of Test...
2.
Immunogenicity of a Booster Dose of Quadrivalent Meningococcal Conjugate Vaccine in Previously Immunized HIV-Infected Children and Youth
Warshaw M, Siberry G, Williams P, Decker M, Jean-Philippe P, Lujan-Zilbermann J
J Pediatric Infect Dis Soc . 2017 Mar; 6(3):e69-e74. PMID: 28339668
Background: The US Advisory Committee on Immunization Practices recommends a booster dose of quadrivalent meningococcal conjugate vaccine (MCV4) after initial immunization for patients at high risk for meningococcal infection. Methods:...
3.
Valganciclovir for symptomatic congenital cytomegalovirus disease
Kimberlin D, Jester P, Sanchez P, Ahmed A, Arav-Boger R, Michaels M, et al.
N Engl J Med . 2015 Mar; 372(10):933-43. PMID: 25738669
Background: The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over...
4.
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate
Havens P, Hazra R, Stephensen C, Kiser J, Flynn P, Wilson C, et al.
Antivir Ther . 2014 Feb; 19(6):613-8. PMID: 24535626
Background: Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D-binding...
5.
Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: fine-mapping for the GC/DBP gene that encodes the vitamin D-binding protein
Porter T, Li X, Stephensen C, Mulligan K, Rutledge B, Flynn P, et al.
Front Genet . 2013 Dec; 4:234. PMID: 24294218
Serum 25-hydroxyvitamin D [25(OH)D] is often deficient (<12 ng/ml) or insufficient (<20 ng/ml) in youth living with human immunodeficiency virus type 1 infection (YLH). Based on evidence from multiple genome-wide...
6.
Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Havens P, Kiser J, Stephensen C, Hazra R, Flynn P, Wilson C, et al.
Antimicrob Agents Chemother . 2013 Sep; 57(11):5619-28. PMID: 24002093
Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by an unknown mechanism(s). Data are limited on tenofovir pharmacokinetics and these effects. Using baseline data from a multicenter study...
7.
Genetic variants in toll-like receptor 2 (TLR2), TLR4, TLR9, and FCγ receptor II are associated with antibody response to quadrivalent meningococcal conjugate vaccine in HIV-infected youth
Spector S, Qin M, Lujan-Zilbermann J, Singh K, Warshaw M, Williams P, et al.
Clin Vaccine Immunol . 2013 Apr; 20(6):900-6. PMID: 23595505
This study examined the association of host genetic variants with the antibody response to the quadrivalent meningococcal conjugate vaccine (MCV4) in HIV-infected youth. Genetic variants associated with severity of meningococcal...
8.
Serum 25-hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection
Havens P, Mulligan K, Hazra R, Flynn P, Rutledge B, Van Loan M, et al.
J Clin Endocrinol Metab . 2012 Aug; 97(11):4004-13. PMID: 22933542
Context: Vitamin D deficiency and insufficiency occur frequently in youth with HIV infection, particularly among those receiving the antiretroviral drug efavirenz. Optimal vitamin D dosing for treatment is unclear. Objective:...
9.
Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus
Lujan-Zilbermann J, Warshaw M, Williams P, Spector S, Decker M, Abzug M, et al.
J Pediatr . 2012 May; 161(4):676-81.e2. PMID: 22622049
Objective: To compare the immunogenicity of 1 vs 2 doses of meningococcal polysaccharide conjugate vaccine (MCV4) in youth infected with human immunodeficiency virus (HIV). Study Design: P1065 was a phase...
10.
Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial
Havens P, Stephensen C, Hazra R, Flynn P, Wilson C, Rutledge B, et al.
Clin Infect Dis . 2012 Jan; 54(7):1013-25. PMID: 22267714
Background: The study goal was to determine the effect of vitamin D (VITD) supplementation on tubular reabsorption of phosphate (TRP), parathyroid hormone (PTH), bone alkaline phosphatase (BAP), and C-telopeptide (CTX)...